[Her2 positive breast cancer: practices]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The Perou and Sørlie molecular classification system categorizes breast tumors into distinct subtypes.
• This classification is crucial for tailoring effective targeted therapies.
• HER2-positive breast cancer represents a significant subtype requiring specific treatment strategies.

Purpose of the Study:

• To review and consolidate pertinent data on HER2-targeted therapies for breast cancer.
• To provide physicians with readily accessible, useful information for daily clinical practice.
• To highlight the role of molecular classification in optimizing treatment selection.

Main Methods:

• Literature review of existing studies and clinical data.
• Focus on therapies targeting the HER2 pathway in breast cancer.
• Synthesis of information on trastuzumab and lapatinib efficacy and application.

Main Results:

• Trastuzumab and lapatinib are established HER2-targeted therapies with proven clinical effectiveness.
• Molecular subtyping, particularly identifying HER2-positive status, is essential for treatment selection.
• Data supports the systematic use of these targeted agents in appropriate patient populations.

Conclusions:

• Effective utilization of targeted therapies in breast cancer relies on accurate molecular classification.
• Trastuzumab and lapatinib are vital treatment options for HER2-positive breast cancer.
• This review offers a practical resource for clinicians managing HER2-positive breast cancer.